Navigation Links
Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
Date:11/27/2007

ndidates in clinical development. In addition to iloperidone, Vanda is developing VEC- 162, a compound for the treatment of sleep and mood disorders which is currently in Phase III development for sleep disorders. Vanda's third product candidate in clinical development, VSF-173, is currently in Phase II development for the treatment of excessive sleepiness. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Note Regarding Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Vanda's plans for its product candidates. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, a failure of Vanda's product candidates to be demonstrably safe and effective, a failure to obtain regulatory approval for the company's products or to comply with ongoing regulatory requirements, a lack of acceptance of Vanda's product candidates in the marketplace, a failure of the company to become or remain profitable, Vanda's inability to obtain the capital necessary to fund its research and development activities, a loss of any of the company's key scientists or management personnel, and other factors that are described in the "Risk Factors" section (Part II, Item 1A)
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Aufgrund der enormen ... erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch die Jahre ... unter pharmaserialisation.com , zeigt die Serialisierungsanforderungen weltweit ... Kraft treten. Für international tätige Unternehmen ... das "ob", sondern darum, "wann" sie die neu ...
(Date:9/19/2014)... , Sept. 19, 2014  CytRx Corporation (Nasdaq: ... company specializing in oncology, today announced that David ... at BioCentury,s 2014 NewsMakers in the Biotech Industry Conference on ... Time. The conference will take place at the Millennium ... . A live and archived webcast of ...
(Date:9/19/2014)...  PCI is pleased to announce it has ... leading provider of Clinical Trial Services and Temperature ... Wales in the United ... presence in the UK/EU to support global investigational ... and distribution capacity, as well as consultative services ...
Breaking Medicine Technology:Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6
... WASHINGTON, Sept. 14, 2011 Labor and management in ... level to support increased protections to fight intellectual property ... to implement those protections." In a ... Pharmaceutical Industry Labor-Management Association ( PILMA ), the group ...
... Pa., Sept. 14, 2011 ECRI Institute ®, ... improving patient care, announces the release of PriceGuide ... advisory service for the procurement of medical-surgical supplies and ... "The 4.0 platform adds a whole new ...
Cached Medicine Technology:PILMA Vows to 'Redouble' Support for Increased Protections Against Intellectual Property Theft 2New PriceGuide 4.0 from ECRI Institute Helps Hospitals Rein in Supply Costs 2New PriceGuide 4.0 from ECRI Institute Helps Hospitals Rein in Supply Costs 3
(Date:9/20/2014)... (PRWEB) September 20, 2014 Villa del ... resort did not experience any damage in relation to ... and activities available. , Hurricane Odile struck Cabo San ... wind, rain and powerful surf conditions. Located on the ... Islands of Loreto experienced some heavy rain, but no ...
(Date:9/20/2014)... On Monday, September 22, Loma Linda ... research grant from Hyundai Hope on Wheels at a ... located on 11234 Anderson St., in Loma Linda. The ... Associate Professor at Loma Linda University and Director of ... children. , Loma Linda University Medical Center ...
(Date:9/20/2014)... (HealthDay News) -- The avian flu that killed 160 ... spread through respiratory drops and therefore poses a potential ... Although no human illnesses have been linked to the ... hospital have discovered natural mutations to the avian H3N8 ... the air in droplets. Current seasonal flu vaccines ...
(Date:9/20/2014)... New PharmaPoint Drug Evaluation report, ... 2023?. The asthma market saw very slow growth ... saturated with relatively efficacious standard therapies, such as ... and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and ... the launch of seven novel targeted biologic agents ...
(Date:9/20/2014)... NC (PRWEB) September 20, 2014 The excitement is ... in Mount Airy, North Carolina. This year the Surry Arts ... draws people from around the country who are still fans of ... Show is a sitcom that aired on CBS from 1960 through ... best show in American television history. Mount Airy, North Carolina ...
Breaking Medicine News(10 mins):Health News:Villa del Palmar at the Islands of Loreto Fully Functioning After Hurricane 2Health News:Villa del Palmar at the Islands of Loreto Fully Functioning After Hurricane 3Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 2Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 3Health News:Avian Flu In Harbor Seals Could Infect People 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4Health News:Mayberry Days Parade Cars will be Provided by Mount Airy Toyota and Mount Airy Chrysler Dodge Jeep Ram 2
... the primary cause of deaths from pneumonia in developing countries ... to a comprehensive new analysis to be released on Thursday, ... International Health , the authors estimate that two pneumococcal ... from the GAVI Alliance could save the lives of three ...
... -- The human jaw shrinks with age and that can result ... found. Swedish researchers looked at plaster molds made of the ... their 20s, and follow-up jaw molds of the same people made ... years there was less and less room for teeth in the ...
... Reporter , WEDNESDAY, Nov. 9 (HealthDay News) -- For the ... solid tumors, in this case non-small cell lung cancers. ... two had a complete response to therapy, one had a ... years after starting therapy. "It,s not a home run, ...
... new study released today offers hope that California may finally ... obesity, but it also showcases a patchwork of progress that ... in obesity rates among school-age children. According ... and Obesity Among California 5th, 7th and 9th Graders, 2005�," ...
... A clinical trial comparing prasugrel to clopidogrel for ... coronary intervention (PCI) was ended early due to relatively ... the primary endpoint at six month follow up. ... In patients underGoing elective stent placement on clopidogrel to ...
... Calif. With an estimated 1.5 million species, fungi represent ... Life . They have an enormous impact on human affairs ... and pathogens, and their partnership with host organisms for mutual ... an accurate understanding of what exactly they do, how they ...
Cached Medicine News:Health News:New studies show progress, value in vaccination against deadly pneumonia 2Health News:New studies show progress, value in vaccination against deadly pneumonia 3Health News:New studies show progress, value in vaccination against deadly pneumonia 4Health News:New Treatment May Boost Survival in Advanced Lung Cancer Cases 2Health News:New Treatment May Boost Survival in Advanced Lung Cancer Cases 3Health News:California making headway in battle against childhood obesity but successes are uneven 2Health News:Results of the TRIGGER-PCI trial reported at TCT 2011 2Health News:International team to sequence genomes of fungi 2Health News:International team to sequence genomes of fungi 3
UROSKOP Access, the dedicated urodiagnostic table with truly unrestricted patient access optimizes nearly all diagnostic and interventional procedures....
Drew Scientific has been making leading edge and top quality CBC systems for over 15 years.,The Excell 16/18 offers a reliable alternative for a 3 part differential....
... therapeutic, expandable turning surface for the BariMaxx™ ... Prevention and treatment of pressure ulcers, Large ... patients using a statuc mattress that would ... whose body weight and size pose a ...
... The BariMaxx™ is a full-featured healthcare bed ... for the care and management of larger ... to 1000 lbs. ,Large patients at risk ... in excess of 1000 lbs. (including accessories), ...
Medicine Products: